Review
Version 1
This version is not peer-reviewed
Exosome Release of Drugs: Coupling with Epithelial-Mesenchymal Transition
Takanori Eguchi
Version 1
: Received: 28 December 2019 / Approved: 29 December 2019 / Online: 29 December 2019 (13:46:21 CET)
How to cite: Eguchi, T.; Ono, K.; Calderwood, S.; Okamoto, K. Exosome Release of Drugs: Coupling with Epithelial-Mesenchymal Transition. Preprints 2019, 2019120386 (doi: 10.20944/preprints201912.0386.v1). Eguchi, T.; Ono, K.; Calderwood, S.; Okamoto, K. Exosome Release of Drugs: Coupling with Epithelial-Mesenchymal Transition. Preprints 2019, 2019120386 (doi: 10.20944/preprints201912.0386.v1).
Abstract
Extracellular vesicles (EVs), such as exosomes or oncosomes are released with molecules unfavorable for survival from cells. In addition, accumulating evidence has shown that tumor cells often eject anti-cancer drugs such as chemotherapeutics and targeted drugs within EVs, a novel mechanism of drug resistance. The EV-releasing, drug resistance phenotype is often coupled with cellular dedifferentiation and transformation, cells undergoing epithelial-mesenchymal transition (EMT) and taking on a cancer stem cell phenotype. Recent studies have shown that the release of EVs is also involved in immunosuppression. The concept of the resistance-associated secretory phenotype (RASP) is reviewed herein.
Subject Areas
resistance-associated secretory phenotype (RASP); extracellular vesicle (EV); exosome; oncosome; drug resistance; epithelial-mesenchymal transition (EMT); heat shock protein (HSP); cell stress response; hypoxia; acidosis; tumor immunology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.
Leave a public commentSend a private comment to the author(s)